$1 on the card-no, page-82

Hope you're hanging in there blackcap. The EPS will in time recover.
I was just looking at Jacobs profit margins, this is a much larger US business involved more in the construction side which is lower margin I think than professional services. Right now consultancies are being squeezed hard but there have always been times like this.
Their takeover of SKM at the height of the resources boom highlights the value in CDD if these things get stupid again.
In 2015 NPAT was 2.3% of sales, so if we assume CDD can achieve this and revenue plateaus I think a low end profit estimate is 27m per annum.
Jacobs makes 7% return on equity which would be 49m in the CDD case - I think this is more likely and doesn't require anyhing from management but a focus on costs.
I don't mean next year here I mean on average, a long term owner should not value the business in cyclical low or high earnings.
Whether you think CDD is selling on a normalised PE of 5 or 10, it's still good value with a large margin of safety for getting things wrong.
Could take many years but $3-4 per share for the patient value investors seems likely.